Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors

Current Drug Metabolism

Volumn 14, Issue 5, 2013, Pages 565-582

  Scaggiante, Bruna ^a   Dapas, Barbara ^a   Farra, Rossella ^a   Grassi, Mario ^a   Pozzato, Gabriele ^b   Giansante, Carlo ^b   Fiotti, Nicola ^b   Tamai, Elisa ^a   Tonon, Federica ^a   Grassi, Gabriele ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Aptamer; Chemical analogues; Drug delivery; EEF1A; Nucleolin; PSMA; SELEX; Tumors

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; CISPLATIN; DOXORUBICIN; GELONIN; NUCLEOLIN; PACLITAXEL; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL VIABILITY; CELLULAR PARAMETERS; CELLULAR UPTAKE; CHEMICAL MODIFICATION; DRUG DELIVERY DEVICE; DRUG STABILITY; IN VIVO STUDY; IONIZING RADIATION; TOXICITY; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; NEOPLASMS;

EID: 84881630470     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/13892002113149990010     Document Type: Article

References (162)

1. Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346, 818-22.
2. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990, 249, 505-10.
3. Pooja, D.; Soyoun, K; Dong-Ki, L. Patents on SELEX and Therapeutic Aptamers. Recent Patents on DNA & Gene Sequences, Volume 2, Number 3, 2008, pp. 172-186.
4. Nitsche, A.; Kurth, A.; Dunkhorst, A.; Pänke, O.; Sielaff, H.; Junge, W.; Muth D.; Scheller, F.; Stöcklein, W.; Dahmen, C.; Pauli, G.; Kage, A. One-step selection of Vaccinia virus-binding DNA aptamers by MonoLEX. BMC Biotechnol., 2007, 7, 48-59.
5. Morris, K.N.; Jensen, K.B.; Julin, C.M.; Weil, M.; Gold, L. High affinity ligands from in vitro selection: complex targets. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 2902-2907. (Pubitemid 28135827)
6. Cerchia, L.; Ducongé, F.; Pestourie, C.; Boulay, J.; Aissouni, Y.; Gombert, K.; Tavitian, B.; de Franciscis, V.; Libri D. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol., 2005, 3, e123.
7. Guo, K.T.; Ziemer, G.; Paul, A.; Wendel, H.P. CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int. J. Mol. Sci., 2008, 9, 668-678. (Pubitemid 351631122)
8. Aquino-Jarquin, G.; Toscano-Garibay J.D. RNA Aptamer Evolution: Two Decades of SELEction. Int. J. Mol. Sci., 2011, 12, 9155-9171.
9. Xiao, Z.; Shangguan D.; Cao Z.; Fang X.; Tan W. Cell-specific internalization study of an aptamer from whole cell selection. Chemistry, 2008, 14, 1769-75.
10. Shangguan, D.; Cao, Z.C.; Li, Y.; Tan, W. Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin. Chem., 2007, 53, 1153-1155. (Pubitemid 46867534)
11. Li, S.; Xu, H.; Ding, H.; Huang, Y.; Cao, X.; Yang, G.; Li, J.; Xie, Z.; Meng, Y.; Li, X.; Zhao, Q.; Shen B.; Shao N. Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J. Pathol., 2009, 218, 327-336.
12. Guo, K.T.; SchAfer, R.; Paul, A.; Gerber, A.; Ziemer, G.; Wendel, H.P. A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. Stem Cells, 2006, 24, 2220-2231. (Pubitemid 44527475)
13. Apte R.S. Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin. Pharmacother., 2008, 9, 499-508. (Pubitemid 351291794)
14. Dougan, H.; Weitz, J.I.; Stafford, A.R.; Gillespie, K.D.; Klement, P.; Hobbs, J.B.; Lyster, D.M. Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents. Nucl. Med. Biol., 2003, 30, 61-72. (Pubitemid 35454163)
15. Grassi, M.; Cavallaro, G.; Scire, S.; Scaggiante, B.; Dapas, B.; Farra, R.; Baiz, D.; Giansante, C.; Guarnieri, G.; Perin, D.; Grassi, G. Current Strategies to Improve the Efficacy and the Delivery of Nucleic Acid Based Drugs. Current Signal Transduction Therapy, Volume 5, Number 2, May 2010, pp. 92-120.
16. Morassutti, C.; Scaggiante, B.; Dapas, B.; Xodo, L.; Tell, G.; Quadrifoglio, F. Effect of phosphorothioate modifications on the ability of GTn oligodeoxynucleotides to specifically recognize single-stranded DNA-binding proteins and to affect human cancer cellular growth. Biochimie, 1999, 81, 1115-1122. (Pubitemid 30006551)
17. Scaggiante, B.; Dapas, B.; Quadrifoglio, F. Alpha-anomeric configuration of GT oligodeoxynucleotide leads to loss of the specific aptameric and cytotoxic properties retained by the beta-anomeric analog. Antisense Nucleic Acid Drug Dev., 2001, 11, 395-399. (Pubitemid 34106805)
18. Mayer, G. The chemical biology of aptamers. Angew Chem. Int. E., Engl., 2009, 48, 2672-2689.
19. Jäger, S.; Rasched, G.; Kornreich-Leshem, H.; Engeser, M.; Thum, O.; Famulok, M. A versatile toolbox for variable DNA functionali-zation at high density. J. Am. Chem. Soc., 2005, 127, 15071-15082. (Pubitemid 41547373)
20. Burmeister, P.E.; Wang, C.; Killough, J.R.; Lewis, S.D.; Horwitz, L.R.; Ferguson A.; Thompson, K.M.; Pendergrast, P.S.; McCauley, T.G.; Kurz, M.; Diener, J.; Cload, S.T.; Wilson, C.; Keefe, A.D. 2'-Deoxy purine, 2'-O-methyl pyrimidine [dRmY]aptamers as candidate therapeutics. Oligonucleotides, 2006, 16, 337-3351.
21. Veedu, R.N.; Vester, B.; Wengel, J. Polymerase chain reaction and transcription using locked nucleic acid nucleotide triphosphates. J. Am. Chem Soc, 2008, 130, 8124-8125. (Pubitemid 351898512)
22. Schmidt, K.S.; Borkowski, S.; Kurreck, J.; Stephens, A.W.; Bald, R.; Hecht, M.; Friebe, M.; Dinkelborg, L.; Erdmann, V.A. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res., 2004, 32, 5757-5765. (Pubitemid 39619159)
23. Campbell, M.A.; Wengel, J. Locked vs. unlocked nucleic acids [LNA vs. UNA]: contrasting structures work towards common therapeutic goals. Chem. Soc. Rev., 2011, 40(12), 5680-9.
24. Ruckman, J.; Green, L.S.; Beeson, J.; Waugh, S.; Gillette, W.L.; Henninger, D.D.; Claesson-Welsh, L.; Janjic, N. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor [VEGF165]. Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem., 1998, 273, 20556-20567. (Pubitemid 28377626)
25. Somasunderam, A.; Thiviyanathan, V; Tanaka, T.; Li, X.; Neerathilingam, M.; Lokesh, G.L.; Mann, A.; Peng, Y.; Ferrari, M.; Klostergaard, J.; Gorenstein, D.G. Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry, 2010, 49, 9106-9112.
26. Wang, R.E.; Wu, H.; Niu, Y.; Cai, J. Improving the stability of aptamers by chemical modification. Curr. Med. Chem., 2011, 8, 4126-4138.
27. Healy, J.M.; Lewis, S.D.; Kurz, M.; Boomer, R.M.; Thompson, K.M.; Wilson, C; McCauley, T.G. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res., 2004, 21, 2234-2246. (Pubitemid 40568437)
28. McCauley, T.G.; Kurz, J.C.; Merlino, P.G.; Lewis, S.D.; Gilbert, M.; Epstein, D.M.; Marsh, H.N. Pharmacologic and pharmacokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor. Pharm. Res., 2006, 23, 303-311. (Pubitemid 43237861)
29. Eulberg, D.; Klussmann, S. Spiegelmers: biostable aptamers. Chembiochem., 2003, 4 (10), 979-983. (Pubitemid 37267585)
30. 32P-labeling of L-deoxyoligonucleotides. Nucleic Acids Res., 2003, 31, e34.
31. Wlotzka B.; Leva S.; Eschgfäller B.; Burmeister J.; Kleinjung F.; Kaduk C; Muhn P.; Hess-Stumpp H.; Klussmann S. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleo-tide-based therapeutic substance class. Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 8898-8902. (Pubitemid 34693655)
32. Maasch C; Vater A.; Buchner K.; Purschke W.G.; Eulberg D.; Vonhoff S.; Klussmann S. Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 [HMGA1] reduce tumor growth in vivo. J. Biol. Chem., 2010, 285, 40012-40018.
33. Theis M.G.; Knorre A.; Kellersch B.; Moelleken J.; Wieland F.; Kolanus W.; Famulok M. Discriminatory aptamer reveals serum response element transcription regulated by cytohesin-2. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 11221-11226. (Pubitemid 39038328)
34. Zhou J.; Rossi JJ. The therapeutic potential of cell-internalizing aptamers. Curr. Top. Med. Chem., 2009, 9, 1144-1157.
35. Wu Y.; Sefah K.; Liu H. Wang R.; Tan W. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 5-10.
36. Forsha S.J.; Panyutin I.V.; Neumann R.D.; Panyutin I.G. Intracellular traffic of oligodeoxynucleotides in and out of the nucleus: effect of exportins and DNA structure. Oligonucleotides, 2010, 20, 277-284.
37. Taghdisi S.M.; Lavaee P.; Ramezani M.; Abnous K. Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes. Eur. J. Pharm. Bio-pharm., 2011, 77, 200-206.
38. Kirpotin D.B.; Drummond D.C.; Shao Y.; Shalaby M.R.; Hong K.; Nielsen U.B.; Marks J.D.; Benz CC; Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res., 2006, 66, 6732-6740. (Pubitemid 44085631)
39. Hicke B.J.; Stephens A.W. Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest., 2000, 106, 923-928.
40. Bagalkot V.; Farokhzad O.C; Langer R.; Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem. Int. Ed. Engl, 2006, 45, 8149-8152. (Pubitemid 44974149)
41. Farokhzad O.C.; Cheng J.; Teply B.A.; Sherifi I.; Jon S.; Kantoff P.W.; Richie J.P.; Langer R. Targeted nanoparticle-aptamer bio-conjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 6315-6320.
42. Dhar S.; Gu F.X.; Langer R.; Farokhzad O.C.; Lippard S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt [IV] prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 17356-17361.
43. Levy-Nissenbaum E.; Radovic-Moreno A.F.; Wang A.Z.; Langer R; Farokhzad O.C. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol., 2008, 26, 442-449.
44. Daniels D.A.; Chen H.; Hicke B.J.; Swiderek K.M.; Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 15416-15421. (Pubitemid 38021004)
45. Midwood K.S.; Hussenet T.; Langlois B.; Orend G. Advances in tenascin-C biology. Cell Mol. Life Sci., 2011, 68, 3175-3199.
46. Chen H.W.; Medley C.D.; Sefah K.; Shangguan D.; Tang Z.; Meng L.; Smith J.E;. Tan W. Molecular recognition of small-cell lung cancer cells using aptamers. Chem. Med. Chem., 2008, 3, 991-1001.
47. Shangguan D.; Meng L.; Cao Z.C.; Xiao Z.; Fang X.; Li Y.; Cardona D.; Witek R.P.; Liu C.; Tan W. Identification of liver cancer-specific aptamers using whole live cells. Anal Chem., 2008, 80, 721-728. (Pubitemid 351206860)
48. Lupold S.E.; Hicke B.J.; Lin Y.; Coffey D.S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res., 2002, 62, 4029-4033. (Pubitemid 34791070)
49. Chu T.C.; Marks J.W. 3rd; Lavery L.A.; Faulkner S.; Rosenblum M.G.; Ellington A.D.; Levy M. Aptamer: toxin conjugates that specifically target prostate tumor cells. Cancer Res., 2006, 66, 5989-5992.
50. Scaggiante B., Dapas B., Farra R., Grassi M., Pozzato G., Giansante C., Fiotti N., Grassi G. Improving siRNA bio-distribution and minimizing side effects. Curr. Drug Metab., 2011, 12, 11-23.
51. McNamara J.O. 2nd; Andrechek E.R.; Wang Y.; Viles K.D.; Rempel R.E.; Gilboa E.; Sullenger B.A.; Giangrande PH. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol., 2006, 24, 1005-1015. (Pubitemid 44215395)
52. Dassie J.P.; Liu X.Y.; Thomas G.S.; Whitaker R.M.; Thiel K.W.; Stockdale K.R.; Meyerholz D.K.; McCaffrey A.P.; McNamara J.O. 2nd; Giangrande P.H. Systemic administration of optimized ap-tamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol., 2009, 27, 839-849.
53. Wullner U.; Neef I.; Eller A.; Kleines M.; Tur M.K.; Barth S. Cell-specific induction of apoptosis by rationally designed bivalent ap-tamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr. Cancer Drug Target., 2008, 8, 554-565.
54. Kim E.; Jung Y.; Choi H.; Yang J.; Suh J.S.; Huh Y.M.; Kim K.; Haam S. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials, 2010, 31, 4592-4599.
55. Tong R.; Yala L.; Fan T.M.; Cheng J. The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells. Biomaterials, 2010, 31, 3043-3053.
56. Dhar S.; Kolishetti N.; Lippard S.J.; Farokhzad O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 1850-1855.
57. Lee I.H.; An S.; Yu M.K.; Kwon H.K.; Im S.H.; Jon S. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bio-conjugates. J. Control. Release, 2011, May 27, in press.
58. Ni X.; Zhang Y.; Ribas J.; Chowdhury W.H.; Castanares M.; Zhang Z.; Laiho M.; Deweese T.L.; Lupold S.E. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J. Clin. Invest., 2011, http://www.jci.org, doi: 10.1172/JCI45109.
59. Min K.; Jo H.; Song K.; Cho M.; Chun Y.S.; Jon S.; Kim W.J.; Ban C. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA [+]and PSMA [-] prostate cancers. Biomaterials, 2011, 32, 2124-2132.
60. Frischmeyer P.A.; Dietz H.C. Nonsense-mediated mRNA decay in health and disease. Hum. Mol. Genet., 1999, 8, 1893-1900. (Pubitemid 29458667)
61. Pastor F.; Kolonias D.; Giangrande P.H.; Gilboa E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature, 2010, 465, 227-230.
62. McNamara J.O.; Kolonias D.; Pastor F.; Mittler R.S.; Chen L.; Giangrande P.H.; Sullenger B.; Gilboa E. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest., 2008, 118, 376-386.
63. Pastor F.; Kolonias D.; McNamara J.O.; Gilboa E. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol. Ther., 2011, 19, 1878-1886.
64. von Mensdorff-Pouilly S.; Snijdewint F.G.; Verstraeten A.A.; Verheijen R.H.; Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int. J. Biol. Markers, 2000, 15, 343-356. (Pubitemid 32041150)
65. Taylor-Papadimitriou J.; Burchell J.; Miles D.W.; Dalziel M. MUC1 and cancer. Biochim. Biophys. Acta, 1999, 1455, 301-313. (Pubitemid 29435996)
66. Hollingsworth M.A.; Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer, 2004, 4, 45-60. (Pubitemid 38082153)
67. Oosterkamp H.M.; Scheiner L.; Stefanova M.C.; Lloyd K.O.; Finstad C.L. Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form [MUC-1/Z]. Int. J. Cancer, 1997, 72, 87-94. (Pubitemid 27314644)
68. Brossart P.; Schneider A.; Dill P.; Schammann T.; Grünebach F.; Wirths S.; Kanz L.; Bühring H.J.; Brugger W. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res., 2001, 61, 6846-6850. (Pubitemid 32896509)
69. Ferreira C.S.M.; Matthews C.S.; Missailidis S. DNA Aptamers That Bind to MUC1 Tumour Marker: Design and Characterization of MUC1-Binding Single-Stranded DNA Aptamers. Tumor Biol., 2006, 27, 289-301. (Pubitemid 44646223)
70. Perkins A.C.; Missailidis S. Radiolabelled aptamers for tumour imaging and therapy. Q J. Nucl. Med. Mol. Imag., 2007, 51, 292-296. (Pubitemid 350267699)
71. Ferreira C.S.; Papamichael K.; Guilbault G.; Schwarzacher T.; Gariepy J.; Missailidis S. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours. Anal Bioanal Chem., 2008, 390, 1039-1050. (Pubitemid 351207802)
72. Pieve C.D.; Perkins A.C.; Missailidis S. Anti-MUC1 aptamers: radiolabelling with [99m]Tc and biodistribution in MCF-7 tumour-bearing mice. Nucl. Med. Biol., 2009, 36, 703-710.
73. Tan L.; Neoh K.G.; Kang E.T.; Choe W.S.; Su X. PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. Macromol. Biosci., 2011, 11, 1331-1335.
74. Ferreira C.S.; Cheung M.C.; Missailidis S.; Bisland S.; Gariépy J. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res., 2009, 37, 866-876.
75. Bruno J.G. Aptamer-biotin-streptavidin-C1q complexes can trigger the classical complement pathway to kill cancer cells. In Vitro Cell Dev. Biol. Anim., 2010, 46, 107-113.
76. Munz M.; Baeuerle P.A.; Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res., 2009, 69, 5627-5629.
77. Schmidt M.; Scheulen M.E.; Dittrich C.; Obrist P.; Marschner N.; Dirix L.; Schmidt M.; Rüttinger D.; Schuler M.; Reinhardt C.; Awada A. An open-label; randomized phase II study of adecatu-mumab; a fully human anti-EpCAM antibody; as monotherapy in patients with metastatic breast cancer. Ann. Oncol., 2010, 21, 275-282.
78. Marschner N.; Rüttinger D.; Zugmaier G.; Nemere G.; Lehmann J.; Obrist P.; Baeuerle P.A.; Wolf A.; Schmidt M.; Abrahamsson P.A.; Reinhardt C.; Heidenreich A. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy. Urol. Int., 2010, 85, 386-395.
79. Shigdar S.; Lin J.; Yu Y.; Pastuovic M.; Wei M.; Duan W. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci., 2011, 102, 991-998.
80. Kanwar J.R.; Roy K.; Kanwar R.K. Chimeric aptamers in cancer cell-targeted drug delivery. Crit. Rev. Biochem. Mol. Biol., 2011, 46, 459-477.
81. Mann A.P.; Bhavane R.C.; Somasunderam A.; Liz Montalvo-Ortiz B.; Ghaghada K.B; Volk D.; Nieves-Alicea R.; Suh K.S; Ferrari M.; Annapragada A.; Gorenstein D.G.; Tanaka T. Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget, 2011, 2, 298-304.
82. Mori T.; Oguro A.; Ohtsu T.; Nakamura Y. RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. Nucleic Acids Res., 2004, 32, 6120-6128. (Pubitemid 40074006)
83. Zhang P.; Zhao N.; Zeng Z.; Feng Y.; Tung C.H.; Chang C.C.; Zu Y. Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. Lab Invest., 2009, 89, 1423-1432.
84. Hsu F.Y.; Zhao Y.; Anderson W.F.; Johnston P.B. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Cancer Invest, 2007, 25, 240-248. (Pubitemid 47026946)
85. Zhao N.; Bagaria H.G.; Wong M.S.; Zu Y. A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. J. Nanobiotechnol, 2011, 9, 2-12.
86. Clarke CA.; Glaser S.L.; Dorfman R.F.; Bracci P.M.; Eberle E.; Holly E.A. Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol. Biomarkers Prev., 2004, 13, 138-143. (Pubitemid 38116631)
87. Mallikaratchy P.; Tang Z.; Kwame S.; Meng L.; Shangguan D.; Tan W. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol. Cell Proteomics, 2007, 6, 2230-2238.
88. Mallikaratchy P.R.; Ruggiero A.; Gardner J.R.; Kuryavyi V.; Maguire W.F.; Heaney M.L.; McDevitt M.R.; Patel D.J.; Scheinberg D.A. A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res., 2011, 39, 2458-2469.
89. Huang Y.F.; Shangguan D.; Liu H.; Phillips J.A.; Zhang X.; Chen Y.; Tan W. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem., 2009, 10, 862-868.
90. Chiquet-Ehrismann R.; Tucker R.P. Connective tissues: signalling by tenascins. Int. J. Biochem. Cell Biol., 2004, 36, 1085-1089. (Pubitemid 38501560)
91. Orend G. Potential oncogenic action of tenascin-C in tumorigene-sis. Int. J. Biochem. Cell Biol, 2005, 37, 1066-1083. (Pubitemid 40311747)
92. Orend G.; Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett, 2006, 244, 143-163. (Pubitemid 44508708)
93. Hicke B.J.; Marion C; Chang Y.F.; Gould T.; Lynott CK.; Parma D.; Schmidt P.G.; Warren S. Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem., 2001, 276, 48644-48654.
94. Hicke B.J.; Stephens A.W.; Gould T.; Chang Y.F.; Lynott CK.; Heil J.; Borkowski S.; Hilger CS.; Cook G.; Warren S.; Schmidt P.G. Tumor targeting by an aptamer. J. Nucl. Med., 2006, 47, 668-678. (Pubitemid 46768469)
95. 99mTc-Mercaptoacetyl-Glu-Glu-aptamer specific for tenascin-C. Molecular Imaging and Contrast Agent Database [MI-CAD] [Internet]. Bethesda [MD]: National Center for Biotechnology Information [US]; 2004-2010. 2008 Jul 17 [updated 2008 Aug 12].
96. Tong R.; Coyle V.J.; Tang L.; Barger A.M.; Fan T.M.; Cheng J. Polylactide nanoparticles containing stably incorporated cyanine dyes for in vitro and in vivo imaging applications. Microsc. Res. Tech., 2010, 73, 901-909.
97. Wang A.Z.; Bagalkot V.; Vasilliou C.C.; Gu F.; Alexis F.; Zhang L.; Shaikh M.; Yuet K.; Cima M.J.; Langer R.; Kantoff P.W.; Bander N.H.; Jon S.; Farokhzad O.C Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. Chem. Med. Chem., 2008, 3, 1311-1315.
98. Savla R.; Taratula O.; Garbuzenko O.; Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control. Release, 2011, 153(1), 16-22.
99. Dapic V.; Abdomerovic V.; Marrington R.; Peberdy J.; Rodger A.; Trent J.O.; Bates P.J. Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic Acids Res., 2003, 31, 2097-2107. (Pubitemid 37442077)
100. Ireson CR.; Kelland L.R. Discovery and development of anticancer aptamers. Mol. Cancer Ther., 2006, 5, 2957-2962. (Pubitemid 46092036)
101. Bates P.J.; Kahlon J.B.; Thomas S.D.; Trent J.O.; Miller D.M. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J. Biol. Chem., 1999, 274, 26369-26377.
102. Dapic V; Bates PJ; Trent JO; Rodger A; Thomas SD; Miller DM. Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry, 2002, 41, 3676-85. (Pubitemid 34224680)
103. Soundararajan S.; Chen W.; Spicer E.K.; Courtenay-Luck N.; Fernandes D.J. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res., 2008, 68, 2358-2365. (Pubitemid 351521810)
104. Mongelard F.; Bouvet P. AS-1411; a guanosine-rich oligonucleo-tide aptamer targeting nucleolin for the potential treatment of cancer; including acute myeloid leukemia. Curr. Opin. Mol. Ther., 2010, 12, 107-114.
105. Storck S.; Shukla M.; Dimitrov S.; Bouvet P. Functions of the histone chaperone nucleolin in diseases. Subcell Biochem., 2007, 41, 125-144.
106. Ishimaru D.; Zuraw L.; Ramalingam S.; Sengupta T.K.; Bandyopadhyay S.; Reuben A.; Fernandes D.J.; Spicer E.K. Mechanism of regulation of bcl-2 mRNA by nucleolin and A+U-rich elementbinding factor 1 [AUF1]. J. Biol. Chem., 2010, 285, 27182-27191.
107. Laber D.A.; Sharma V.R.; Bhupalam L.; Taft B.; Hendler F.J.; Barnhart K.M. Update on the first phase I study of AGRO100 in advanced cancer. J. Clin. Oncol., 2005, 23, 3064.
108. Bates P.J.; Laber D.A.; Miller D.M.; Thomas S.D.; Trent J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol., 2009, 86, 151-164.
109. Watanabe T.; Hirano K.; Takahashi A.; Yamaguchi K.; Beppu M. Fujiki H.; Suganuma M. Nucleolin on the cell surface as a new molecular target for gastric cancer treatment. Biol. Pharm. Bull., 2010, 33, 796-803.
110. Teng Y; Girvan AC; Casson LK; Pierce WM Jr; Qian M; Thomas SD; Bates PJ. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res., 2007, 67, 10491-500. (Pubitemid 350070825)
111. Reyes-Reyes E.M.; Teng Y.; Bates PJ. A new paradigm for ap-tamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res., 2010, 70, 8617-8629.
112. Soundararajan S.; Wang L.; Sridharan V.; Chen W.; Courtenay-Luck N.; Jones D.; Spicer E.K.; Fernandes D.J. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol. Pharmacol., 2009, 76, 984-991.
113. Cao Z.; Tong R.; Mishra A.; Xu W.; Wong G.C.; Cheng J.; Lu Y. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem. Int. Ed. Engl., 2009, 48, 6494-6498.
114. Feng L.; Chen Y.; Ren J.; Qu X. A graphene functionalized electrochemical aptasensor for selective label-free detection of cancer cells. Biomaterials, 2011, 32, 2930-2937.
115. Guo J.; Gao X.; Su L.; Xia H.; Gu G.; Pang Z.; Jiang X.; Yao L.; Chen J.; Chen H. Aptamer-functionalized PEG-PLGA nanoparti-cles for enhanced anti-glioma drug delivery. Biomaterials, 2011, 32, 8010-8120.
116. Ai J.; Guo W.; Li B.; Li T.; Li D.; Wang E. DNA G-quadruplex-templated formation of the fluorescent silver nanocluster and its application to bioimaging. Talanta, 2012, 88, 450-455.
117. Dougall W.C.; Qian X.; Greene M.I. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. J. Cell Biochem., 1993, 53, 61-73. (Pubitemid 23287334)
118. Krähn G.; Leiter U.; Kaskel P.; Udart M.; Utikal J.; Bezold G.; Peter R.U. Coexpression patterns of EGFR; HER2; HER3 and HER4 in non-melanoma skin cancer. Eur. J. Cancer, 2001, 37, 251-259. (Pubitemid 32144704)
119. Chen X.; Yeung T.K.; Wang Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem. Bio-phys. Res. Commun., 2000, 277, 757-763.
120. Chen C.H.; Chernis G.A.; Hoang V.Q.; Landgraf R. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 9226-9231. (Pubitemid 37033911)
121. Dastjerdi K.; Tabar G.H.; Dehghani H.; Haghparast A. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Biotechnol. Appl. Biochem., 2011, 58, 226-230.
122. Hansford J.R.; Mulligan L.M. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J. Med. Genet., 2000, 37, 817-827.
123. Vento M.T.; Iuorio M.; Netti P.A.; Ducongè F.; Tavitian B.; Franciscis V.; Cerchia L. Distribution and bioactivity of the Ret-specific D4 aptamer in three-dimensional collagen gel cultures. Mol. Cancer Ther., 2008, 7, 3381-3388.
124. Leik C.E.; Su E.J.; Nambi P.; Crandall D.L.; Lawrence D.A. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J. Thromb. Haemost,. 2006, 4, 2710-2715. (Pubitemid 44741569)
125. Palmieri D.; Lee J.W.; Juliano R.L;. Church F.C. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J. Biol. Chem., 2002, 277, 40950-40957. (Pubitemid 35215683)
126. Blake C.M.; Sullenger B.A.; Lawrence D.A.; Fortenberry Y.M. Antimetastatic potential of PAI-1-specific RNA aptamers. Oli-gonucleotides, 2009, 19, 117-128.
127. Madsen J.B; Dupont D.M.; Andersen T.B.; Nielsen A.F.; Sang L.; Brix D.M.; Jensen J.K.; Broos T.; Hendrickx M.L.; Christensen A.; Kjems J.; Andreasen P.A. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1. Biochemistry, 2010, 49, 4103-4115.
128. Lu C.; Thaker P.H.; Lin Y.G.; Spannuth W.; Landen C.N.; Merritt W.M.; Jennings N.B.; Langley R.R.; Gershenson D.M.; Yancopoulos G.D.; Ellis L.M.; Jaffe R.B.; Coleman R.L.; Sood A.K. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am. J. Obstet. Gynecol., 2008, 198, 477.e1-47810.
129. Sennino B.; Falcon B.L.; McCauley D.; Le T.; McCauley T.; Kurz J.C.; Haskell A.; Epstein D.M.; McDonald D.M. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res., 2007, 67, 7358-7367. (Pubitemid 47206566)
130. Lu C.; Shahzad M.M.; Moreno-Smith M.; Lin Y.G.; Jennings N.B.; Allen J.K.; Landen C.N.; Mangala L.S.; Armaiz-Pena G.N.; Schmandt R.; Nick A.M.; Stone R.L.; Jaffe R.B.; Coleman R.L.; Sood A.K. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol. Ther., 2010, 9, 176-182.
131. Falcon B.L.; Pietras K.; Chou J.; Chen D.; Sennino B.; Hanahan D.; McDonald D.M. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. Am J. Pathol., 2011, 178, 2920-2930.
132. Mi J.; Zhang X.; Giangrande P.H.; McNamara J.O. 2nd; Nimjee S.M.; Sarraf-Yazdi S.; Sullenger B.A.; Clary B.M. Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothe-lial cell growth and survival. Biochem. Biophys. Res. Commun., 2005, 338, 956-963. (Pubitemid 41597735)
133. White R.R.; Roy J.A.; Viles K.D.; Sullenger B.A.; Kontos C.D. A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function. Angiogenesis, 2008, 11, 395-401.
134. Sarraf-Yazdi S.; Mi J.; Moeller B.J.; Niu X.; White R.R.; Kontos C.D.; Sullenger B.A.; Dewhirst M.W.; Clary B.M. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J. Surg. Res., 2008, 146, 16-23. (Pubitemid 351442931)
135. Strobel T.; Swanson L.; Cannistra S.A. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res., 1997, 57, 1228-1232. (Pubitemid 27152541)
136. Alaniz L.; Rizzo M.; Malvicini M.; Jaunarena J.; Avella D.; Atorrasagasti C.; Aquino J.B.; Garcia M.; Matar P.; Silva M.; Mazzolini G. Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response. Cancer Lett., 2009, 278, 9-16.
137. Mani S.A.; Guo W.; Liao M.J.; Eaton E.N.; Ayyanan A.; Zhou A.Y.; Brooks M.; Reinhard F.; Zhang C.C.; Shipitsin M.; Campbell L.L.; Polyak K.; Brisken C.; Yang J.; Weinberg R.A. The epithe-lial-mesenchymal transition generates cells with properties of stem cells. Cell, 2008, 133, 704-715. (Pubitemid 351636299)
138. Wai P.Y.; Kuo P.C. The role of Osteopontin in tumor metastasis. J. Surg. Res., 2004, 121, 228-241. (Pubitemid 39387464)
139. Mi Z.; Guo H.; Russell M.B.; Liu Y.; Sullenger B.A.; Kuo P.C. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol. Ther., 2009, 17, 153-161.
140. Talbot L.J.; Mi Z.; Bhattacharya S.D.; Kim V.; Guo H.; Kuo P.C. Pharmacokinetic characterization of an RNA aptamer against os-teopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. Surgery, 2011, 150, 224-230.
141. Hunter C.; Bond J.; Kuo P.C.; Selim M.A.; Levinson H. The Role of Osteopontin and Osteopontin Aptamer (OPN-R3) in Fibroblast Activity. J. Surg. Res., 2011.
142. Bhattacharya S.D.; Mi Z.; Kim V.M.; Guo H.; Talbot L.J.; Kuo P.C. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. Ann. Surg., 2012, 255, 319-325.
143. Pashenkov M.; Goëss G.; Wagner C.; Hörmann M.; Jandl T.; Moser A.; Britten C.M.; Smolle J.; Koller S.; Mauch C.; Tantcheva-Poor I.; Grabbe S.;
144. Zent C.S.; Smith B.J.; Ballas Z.K.; Wooldridge J.E.; Link B.K.; Call T.G.; Shanafelt T.D.; Bowen D.A.; Kay N.E.; Witzig T.E.; Weiner G.J. A Phase I Clinical Trial of CpG Oligonucleotide 7909 [PF-03512676] in Patients with Previously Treated Chronic Lymphocytic Leukemia. Leuk Lymphoma, 2011, sept. 19, in press.
145. Mi J.; Liu Y.; Rabbani Z.N.; Yang Z.; Urban J.H.; Sullenger B.A.; Clary B.M. In vivo selection of tumor-targeting RNA motifs. Nat. Chem. Biol., 2010, 6, 22-24.
146. Zueva E.; Rubio L.I.; Ducongé F.; Tavitian B. Metastasis-focused cell-based SELEX generates aptamers inhibiting cell migration and invasion. Int. J. Cancer, 2011, 128, 797-804.
147. Bala J.; Bhaskar A. Varshney A.; Singh A.K.; Dey S.; Yadava P. In vitro selected RNA aptamer recognizing glutathione induces ROS mediated apoptosis in the human breast cancer cell line MCF 7. RNA Biol., 2011, 8, 101-111.
148. Zhang L.; Yoo S.; Dritschilo A.; Belyaev I.; Soldatenkov V. Targeting Ku protein for sensitizing of breast cancer cells to DNA-damage. Int. J. Mol. Med., 2004, 14, 153-159.
149. Mantovani A. Molecular pathways linking inflammation and cancer. Curr. Mol. Med., 2010, 10, 369-373.
150. Mi J.; Zhang X.; Rabbani Z.N.; Liu Y.; Reddy S.K.; Su Z.; Salahuddin F.K.; Viles K.; Giangrande P.H.; Dewhirst M.W.; Sullenger B.A.; Kontos C.D.; Clary B.M. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol. Ther., 2008, 16, 66-73.
151. Chan R.; Gilbert M.; Thompson K.M.; Marsh H.N.; Epstein D.M.; Pendergrast P.S. Co-expression of anti-NFkappaB RNA aptamers and siRNAs leads to maximal suppression of NFkappaB activity in mammalian cells. Nucleic Acids Res., 2006, 34, e36.
152. Wurster S.E.; Maher L.J. 3rd. Selection and characterization of anti-NF-kappaB p65 RNA aptamers. RNA, 2008, 14, 1037-1047. (Pubitemid 351717485)
153. Townshend B.; Aubry I.; Marcellus R.C.; Gehring K.; Tremblay M.L. An RNA aptamer that selectively inhibits the enzymatic activity of protein tyrosine phosphatase 1B in vitro. Chembiochem., 2010, 11, 1583-1593.
154. Jeong S.; Han S.R.; Lee Y.J.; Kim J.H.; Lee S.W. Identification of RNA aptamer specific to mutant KRAS protein. Oligonucleotides, 2010, 20, 155-161.
155. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer, 2003, 3, 11-22. (Pubitemid 37328883)
156. Scaggiante B.; Morassutti C.; Dapas B.; Tolazzi G.; Ustulin F.; Quadrifoglio F. Human cancer cell lines growth inhibition by GTn oligodeoxyribonucleotides recognizing single-stranded DNA-binding proteins. Eur. J. Biochem., 1998, 252, 207-215. (Pubitemid 28101995)
157. Morassutti C.; Dapas B.; Scaggiante B.; Paroni G.; Xodo L.; Quadrifoglio F. Effect of oligomer length and base substitutions on the cytotoxic activity and specific nuclear protein recognition of GTn oligonucleotides in the human leukemic CCRF-CEM cell line. Nucleosides Nucleotides, 1999, 18, 1711-1716. (Pubitemid 29362372)
158. Dapas B.; Perissin L.; Pucillo C.; Quadrifoglio F; Scaggiante B. Increase in therapeutic index of doxorubicin and vinblastine by ap-tameric oligonucleotide in human T lymphoblastic drug-sensitive and multidrug-resistant cells. Antisense Nucleic Acid Drug Dev., 2002, 12, 247-255.
159. Dapas B.; Tell G.; Scaloni A.; Pines A.; Ferrara L.; Quadrifoglio F.; Scaggiante B. Identification of different isoforms of eEF1A in the nuclear fraction of human T-lymphoblastic cancer cell line specifically binding to aptameric cytotoxic GT oligomers. Eur. J. Bio-chem., 2003, 270, 3251-3262. (Pubitemid 36930191)
160. Scaggiante B.; Dapas B.; Perissin L.; Manzini G. Aptameric GT oligomers need to be complexed to ethoxylated polyethylenimine as pre-paired duplexes to efficiently exert their cytotoxic activity in human lymphoblastic cancer cells. Biochimie, 2005, 87, 713-723. (Pubitemid 41058902)
161. Scaggiante B.; Dapas B.; Grassi G.; Manzini G. Interaction of G-rich GT oligonucleotides with nuclear-associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines. FEBS J., 2006, 273, 1350-1361. (Pubitemid 44029102)
162. Scaggiante B; Dapas B.; Bonin S.; Grassi M.; Zennaro C.; Farra R.; Cristiano L.; Siracusano S.; Zanconati F.; Giansante C.; Grassi G. Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression. Br. J. Cancer, 2012, 106, 166-173.